MedAssets (Nasdaq: MDAS ) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MedAssets's revenues will grow 7.4% and EPS will decrease 0.0%.
The average estimate for revenue is $154.2 million. On the bottom line, the average EPS estimate is $0.26.
Last quarter, MedAssets logged revenue of $163.0 million. GAAP reported sales were 11% higher than the prior-year quarter's $147.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.28. GAAP EPS were $0.04 for Q2 versus -$0.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 78.7%, 60 basis points worse than the prior-year quarter. Operating margin was 12.3%, 160 basis points worse than the prior-year quarter. Net margin was 1.4%, 310 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $627.5 million. The average EPS estimate is $1.11.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 62 members out of 75 rating the stock outperform, and 13 members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give MedAssets a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $16.37.